Pre- and post-conditioning treatment with an ultra-low dose of Δ9-tetrahydrocannabinol (THC) protects against pentylenetetrazole (PTZ)-induced cognitive damage

Behavioural Brain Research

Volumn 220, Issue 1, 2011, Pages 194-201

  Assaf, Fadi ^a   Fishbein, Miriam ^a   Gafni, Mikhal ^a   Keren, Ora ^a   Sarne, Yosef ^a  

^a TEL AVIV UNIVERSITY   (Israel)

Author keywords

Cannabinoid; Cognitive deficit; Epileptic seizures; Neuroprotection; Postconditioning; Preconditioning

Indexed keywords

DRONABINOL; MITOGEN ACTIVATED PROTEIN KINASE; PENTETRAZOLE;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BEHAVIORAL RESEARCH; BIOCHEMISTRY; CEREBELLUM; COGNITIVE DEFECT; DOSE RESPONSE; DRUG EFFICACY; ENZYME INHIBITION; LEARNING; LOW DRUG DOSE; MEMORY; MOUSE; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; SINGLE DRUG DOSE;

ANALYSIS OF VARIANCE; ANIMALS; BEHAVIOR, ANIMAL; COGNITION DISORDERS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; GABA ANTAGONISTS; MALE; MAZE LEARNING; MICE; MICE, INBRED ICR; NEUROPSYCHOLOGICAL TESTS; PENTYLENETETRAZOLE; PSYCHOTROPIC DRUGS; REACTION TIME; RECOGNITION (PSYCHOLOGY); TETRAHYDROCANNABINOL; TIME FACTORS;

EID: 79952087921     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2011.02.005     Document Type: Article

References (52)

1. Agell N., Bachs O., Rocamora N., Villalonga P. Modulation of the Ras/Raf/MEK/ERK pathway by Ca(2+), and calmodulin. Cell. Signal. 2002, 14:649-654.
2. Amal H., Fridman-Rozevich L., Senn R., Strelnikov A., Gafni M., Keren O., et al. Long-term consequences of a single treatment of mice with an ultra-low dose of Δ9-tetrahydrocannabinol (THC). Behav. Brain Res. 2010, 206:245-253.
3. Bladin C.F., Alexandrov A.V., Bellavance A., Bornstein N., Chambers B., Cote R., et al. Seizures after stroke: a prospective multicenter study. Arch. Neurol. 2000, 57:1617-1622.
4. Braida D., Pozzi M., Sala M. CP 55,940 protects against ischemia-induced electroencephalographic flattening and hyperlocomotion in Mongolian gerbils. Neurosci. Lett. 2000, 296:69-72.
5. Charriaut-Marlangue C., Aggoun-Zouaoui D., Represa A., Ben-Ari Y. Apoptotic features of selective neuronal death in ischemia, epilepsy and gp 120 toxicity. Trends Neurosci. 1996, 19:109-114.
6. Christensen J., Pedersen M.G., Pedersen C.B., Sidenius P., Olsen J., Vestergaard M. Long-term risk of epilepsy after traumatic brain injury in children and young adults: a population-based cohort study. Lancet 2009, 373:1105-1110.
7. Clark R.E., Broadbent N.J., Squire L.R. Hippocampus and remote spatial memory in rats. Hippocampus 2005, 15:260-272.
8. Clement A.B., Hawkins E.G., Lichtman A.H., Cravatt B.F. Increased seizure susceptibility and proconvulsant activity of anandamide in mice lacking fatty acid amide hydrolase. J. Neurosci. 2003, 23:3916-3923.
9. De Reuck J., Claeys I., Martens S., Vanwalleghem P., Van Maele G., Phlypo R., et al. Computed tomographic changes of the brain and clinical outcome of patients with seizures and epilepsy after an ischaemic hemispheric stroke. Eur. J. Neurol. 2006, 13:402-407.
10. Dere E., Huston J.P., De Souza Silva M.A. The pharmacology, neuroanatomy and neurogenetics of one-trial object recognition in rodents. Neurosci. Biobehav. Rev. 2007, 31:673-704.
11. Derkinderen P., Valjent E., Toutant M., Corvol J.C., Enslen H., Ledent C., et al. Regulation of extracellular signal-regulated kinase by cannabinoids in hippocampus. J. Neurosci. 2003, 23:2371-2382.
12. Di Marzo V. Targeting the endocannabinoid system: to enhance or reduce?. Nat. Rev. Drug Discov. 2008, 7:438-455.
13. Dirnagl U., Becker K., Meisel A. Preconditioning and tolerance against cerebral ischaemia: from experimental strategies to clinical use. Lancet Neurol 2009, 8:398-412.
14. Fowler C.J., Rojo M.L., Rodriguez-Gaztelumendi A. Modulation of the endocannabinoid system: neuroprotection or neurotoxicity?. Exp. Neurol. 2010, 224:37-47.
15. Galve-Roperh I., Aguado T., Palazuelos J., Guzman M. Mechanisms of control of neuron survival by the endocannabinoid system. Curr. Pharm. Des. 2008, 14:2279-2288.
16. Gidday J.M. Cerebral preconditioning and ischaemic tolerance. Nat. Rev. Neurosci. 2006, 7:437-448.
17. Golanov E.V., Zhou P. Neurogenic neuroprotection. Cell. Mol. Neurobiol. 2003, 23:651-663.
18. Hausenloy D.J., Yellon D.M. Preconditioning and postconditioning: underlying mechanisms and clinical application. Atherosclerosis 2009, 204:334-341.
19. Hausenloy D.J., Yellon D.M. Survival kinases in ischemic preconditioning and postconditioning. Cardiovasc. Res. 2006, 70:240-253.
20. Hayakawa K., Mishima K., Nozako M., Hazekawa M., Ogata A., Fujioka M., et al. Δ9-tetrahydrocannabinol (Δ9-THC) prevents cerebral infarction via hypothalamic-independent hypothermia. Life Sci. 2007, 80:1466-1471.
21. Huang L.T., Yang S.N., Liou C.W., Hung P.L., Lai M.C., Wang C.L., et al. Pentylenetetrazol-induced recurrent seizures in rat pups: time course on spatial learning and long-term effects. Epilepsia 2002, 43:567-573.
22. Kitagawa K., Matsumoto M., Kuwabara K., Tagaya M., Ohtsuki T., Hata R., et al. 'Ischemic tolerance' phenomenon detected in various brain regions. Brain Res. 1991, 561:203-211.
23. Lamberty Y., Klitgaard H. Consequences of pentylenetetrazole kindling on spatial memory and emotional responding in the rat. Epilepsy Behav 2000, 1:256-261.
24. Liou A.K., Clark R.S., Henshall D.C., Yin X.M., Chen J. To die or not to die for neurons in ischemia, traumatic brain injury and epilepsy: a review on the stress-activated signaling pathways and apoptotic pathways. Prog. Neurobiol. 2003, 69:103-142.
25. Mitchell A.J., Kemp S., Benito-Leon J., Reuber M. The influence of cognitive impairment on health-related quality of life in neurological disease. Acta Neuropsychiatrica 2010, 22:2-13.
26. Murry C.E., Jennings R.B., Reimer K.A. Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation 1986, 74:1124-1136.
27. Nagayama T., Sinor A.D., Simon R.P., Chen J., Graham S.H., Jin K., et al. Cannabinoids and neuroprotection in global and focal cerebral ischemia and in neuronal cultures. J. Neurosci. 1999, 19:2987-2995.
28. Obrenovitch T.P. Molecular physiology of preconditioning-induced brain tolerance to ischemia. Physiol. Rev. 2008, 88:211-247.
29. Pacher P., Hasko G. Endocannabinoids and cannabinoid receptors in ischaemia-reperfusion injury and preconditioning. Br. J. Pharmacol. 2008, 153:252-262.
30. Panikashvili D., Simeonidou C., Ben-Shabat S., Hanus L., Breuer A., Mechoulam R., et al. An endogenous cannabinoid (2-AG) is neuroprotective after brain injury. Nature 2001, 413:527-531.
31. Pertwee R.G. Emerging strategies for exploiting cannabinoid receptor agonists as medicines. Br. J. Pharmacol. 2009, 156:397-411.
32. Pignataro G., Meller R., Inoue K., Ordonez A.N., Ashley M.D., Xiong Z., et al. In vivo and in vitro characterization of a novel neuroprotective strategy for stroke: ischemic postconditioning. J. Cereb. Blood Flow Metab. 2008, 28:232-241.
33. Pignataro G., Scorziello A., Di Renzo G., Annunziato L. Post-ischemic brain damage: effect of ischemic preconditioning and postconditioning and identification of potential candidates for stroke therapy. FEBS J 2009, 276:46-57.
34. Pitkanen A., Immonen R.J., Grohn O.H., Kharatishvili I. From traumatic brain injury to posttraumatic epilepsy: what animal models tell us about the process and treatment options. Epilepsia 2009, 50(Suppl 2):21-29.
35. Reis D.J., Kobylarz K., Yamamoto S., Golanov E.V. Brief electrical stimulation of cerebellar fastigial nucleus conditions long-lasting salvage from focal cerebral ischemia: conditioned central neurogenic neuroprotection. Brain Res. 1998, 780:161-165.
36. Rubino T., Forlani G., Vigano D., Zippel R., Parolaro D. Modulation of extracellular signal-regulated kinases cascade by chronic delta 9-tetrahydrocannabinol treatment. Mol. Cell. Neurosci. 2004, 25:355-362.
37. Rutten A., van Albada M., Silveira D.C., Cha B.H., Liu X., Hu Y.N., et al. Memory impairment following status epilepticus in immature rats: time-course and environmental effects. Eur. J. Neurosci. 2002, 16:501-513.
38. Sankar R., Shin D.H., Liu H., Mazarati A., Pereira de Vasconcelos A., Wasterlain C.G. Patterns of status epilepticus-induced neuronal injury during development and long-term consequences. J. Neurosci. 1998, 18:8382-8393.
39. Senn R., Keren O., Hefetz A., Sarne Y. Long-term cognitive deficits induced by a single, extremely low dose of tetrahydrocannabinol (THC): behavioral, pharmacological and biochemical studies in mice. Pharmacol Biochem Behav 2008, 88:230-237.
40. Shouman B., Fontaine R.H., Baud O., Schwendimann L., Keller M., Spedding M., et al. Endocannabinoids potently protect the newborn brain against AMPA-kainate receptor-mediated excitotoxic damage. Br. J. Pharmacol. 2006, 148:442-451.
41. Sommer C. Neuronal plasticity after ischemic preconditioning and TIA-like preconditioning ischemic periods. Acta Neuropathol 2009, 117:511-523.
42. Tanay E., Mundel P., Sommer C. Short-term ischemia usually used for ischemic preconditioning causes lose of dendritic integrity after long-term survival in the gerbil hippocampus. Brain Res. 2006, 1112:222-226.
43. Troy C.M., Friedman J.E., Friedman W.J. Mechanisms of p75-mediated death of hippocampal neurons. Role of caspases. J. Biol. Chem. 2002, 277:34295-34302.
44. Tselnicker I., Keren O., Hefetz A., Pick C.G., Sarne Y. A single low dose of tetrahydrocannabinol induces long-term cognitive deficits. Neurosci. Lett. 2007, 411:108-111.
45. van der Stelt M., Veldhuis W.B., Bar P.R., Veldink G.A., Vliegenthart J.F., Nicolay K. Neuroprotection by Delta9-tetrahydrocannabinol, the main active compound in marijuana, against ouabain-induced in vivo excitotoxicity. J. Neurosci. 2001, 21:6475-6479.
46. van der Stelt M., Veldhuis W.B., van Haaften G.W., Fezza F., Bisogno T., Bar P.R., et al. Exogenous anandamide protects rat brain against acute neuronal injury in vivo. J. Neurosci. 2001, 21:8765-8771.
47. Viscomi M.T., Oddi S., Latini L., Bisicchia E., Maccarrone M., Molinari M. The endocannabinoid system: a new entry in remote cell death mechanisms. Exp. Neurol. 2010, 224:56-65.
48. Wang P., Wang W.P., Sun Z., Wang H.X., Yan L., Fan Y.H. Impaired spatial learning related with decreased expression of calcium/calmodulin-dependent protein kinase II alpha and cAMP-response element binding protein in the pentylenetetrazol-kindled rats. Brain Res. 2008, 1238:108-117.
49. Zaleska M.M., Mercado M.L., Chavez J., Feuerstein G.Z., Pangalos M.N., Wood A. The development of stroke therapeutics: promising mechanisms and translational challenges. Neuropharmacology 2009, 56:329-341.
50. Zemke D., Smith J.L., Reeves M.J., Majid A. Ischemia and ischemic tolerance in the brain: an overview. Neurotoxicology 2004, 25:895-904.
51. Zhao H. Ischemic postconditioning as a novel avenue to protect against brain injury after stroke. J. Cereb. Blood Flow Metab. 2009, 29:873-885.
52. Zhao Z.Q., Vinten-Johansen J. Postconditioning: reduction of reperfusion-induced injury. Cardiovasc. Res. 2006, 70:200-211.